William P. Tew

GlycoMira Therapeutics, Inc. is a preclinical-stage biopharmaceutical company based in Salt Lake City, UT. The private company is dedicated to improving the standard of care and outcomes for patients with cancer and other inflammatory diseases. GlycoMira is developing a new class of innate immune system modulators based on polysaccharides that naturally occur within the body. The company's lead drug candidate, GM-1111, has demonstrated potential to address unmet needs in solid tumor treatment and supportive care. The CEO of the company is William P. Tew.

Cangene bioPharma LLC provides commercial drug production services. It offers ecosystem studies and restoration science, fisheries, and environmental chemistry and toxicology services. The company was founded by William P. Tew, Paul Wilks and Samuel Cross in 1980 and is headquartered in Solomons, MD.

Part of Lineage Cell Therapeutics, Inc., OrthoCyte Corp. develops cellular therapeutics for orthopedic repair diseases and injuries. The company is based in Alameda, CA. The CEO of the company is Michael D. West.

Glycosan BioSystems, Inc. develops, manufactures, and markets formulations of a hyaluronan-based synthetic extra cellular matrix. Its products are used cell culture, stem cell culture, tissue engineering, and cell therapy. The company was founded by Glenn Prestwich, William Tew, and Anna Scott in January 2006 and is located in Salt Lake City, UT.

Carterra, Inc. engages in provision of innovative technologies designed to accelerate the discovery of novel therapeutic candidates. It offers Kinetics software, Epitope mapping, therapeutic areas, and antibody formats. The company was founded by James Smith and Josh Eckman in 2005 and is headquartered in Salt Lake City, UT.

NMGF Management LLC (New Markets Venture Partners) is a venture capital firm founded in 2002 by Mark Anthony Grovic and Robb Tyler Doub. The firm is headquartered in Fulton, Maryland.